相关临床试验
206
59 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
5
2.4%
已完成
106
51.5%
Enrolling By Invitation
2
1.0%
尚未招募
52
25.2%
招募中
31
15.1%
Unknown
10
4.8%
暂无批准数据
- Liv Hospital and Istinye University have signed a comprehensive collaboration with the University of Pennsylvania's Perelman School of Medicine to develop CAR-T cell therapy and proton therapy capabilities in Turkey. - The partnership will establish good-manufacturing-practice cell production laboratories in Istanbul to produce CAR-T therapies locally, potentially reducing treatment delays and shipping costs. - Early-stage trials will focus on relapsed or refractory multiple myeloma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia, with plans to expand to autoimmune disorders. - A multi-room proton therapy center is planned at Liv's oncology campus to serve regional needs and reduce patient travel to other countries for advanced cancer treatment.
- First-line cemiplimab (Libtayo) monotherapy demonstrated a remarkable survival advantage over chemotherapy in advanced NSCLC patients with PD-L1 ≥50% and brain metastases, with median OS of 52.4 vs 20.7 months. - The EMPOWER-Lung 1 trial's 5-year follow-up data confirms cemiplimab's long-term clinical benefits across all PD-L1 expression levels, with the greatest benefit observed in patients with PD-L1 ≥90%. - Patients receiving cemiplimab experienced fewer grade ≥3 adverse events compared to chemotherapy (18.3% vs 39.9%), while also reporting improved quality of life measures including better emotional functioning and reduced fatigue.
